Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En immunogenisitet og sikkerhetsforsøk av MVA-BN hos voksne som lever med HIV for forebygging av MPOX-infeksjon, i Kinshasa, DRC (Mbote-HIVAX)

17. november 2026 oppdatert av: Institute of Tropical Medicine, Belgium

MPOX -biologien, utfallet, overføringen og epidemiologiprosjektet - HIV -immunisering og vaksinasjon mot MPOX -eksponeringsforsøk

This is an open-label, phase 2, immunogenicity and safety trial of the MVA-BN vaccine for the prevention of mpox in adults living with HIV with different level of CD4 counts in Kinshasa, DRC.

The study team aims to investigate whether the administration of 2 standard subcutaneous doses of the Modified Vaccinia Ankara of Bavarian Nordic (MVA-BN) vaccine given 28 days apart, is immunogenic and safe when administered to People Living with HIV (PLHIV) with different levels of CD4 counts in the Democratic Republic of the Congo (DRC).

Enrollment will be stratified according to three different subgroups based on CD4 counts assessed during visit 1A: <200 cells/µL; 200 to 499 cells/µL; ≥ 500 cells/µL. A total of 600 participants will be included in the trial, with 200 participants per subgroup.

All participants will be invited to 6 trial visits over a period of 7 months.

This study will take place in cooperation with the National Programme for the Fight against AIDS (PNLS), the 'Programme Elargi de Vaccination (PEV)' and the 'Institut National de Santé Publique (INSP)'. As part of the response to the current mpox epidemic in DRC, a large cohort of about 10,000 individuals living in Kinshasa will be vaccinated in this program. Vaccination will take place in the Centre Hospitalier Kabinda (CHK) and the Pakadjuma Health Centre. All people living with HIV (PLHIV) with the intention to be vaccinated in the CHK, will be asked for their willingness to participate in the MBOTE-HIVAX clinical trial until the sample size of 600 participants needed for this clinical trial is reached.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Studietype

Intervensjonell

Registrering (Antatt)

600

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 45 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years and ≤ 45 years at time of informed consent
  • Able and willing to provide written informed consent
  • Infected with HIV and receiving combination antiretroviral therapy (ART) for ≥ 8 weeks prior to study entry and vaccination
  • Preparedness to follow the study schedule
  • Willingness to use contraception for 1 month after each vaccination (only for women of childbearing potential)

Exclusion Criteria:

  • A known history of mpox and/or smallpox
  • A known history of vaccination with 1st, 2nd or 3rd generation smallpox vaccines, or vaccine platforms that contain MVA as a vector
  • Planned MVA-based vaccination (other than study vaccination) during the trial
  • Close contact to a confirmed mpox case in the 3 weeks prior to study enrollment
  • Uncontrolled severe infection or other condition requiring hospitalization
  • Pregnancy
  • History of anaphylaxis or severe allergic reaction to any vaccine or known allergy to one of the components of the study vaccine

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: CD4 <200

Participants in this arm are stratified in the group with participants with a CD4 level below 200cells/µL.

All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28.

Eksperimentell: CD4 200-499

Participants in this arm are stratified in the group with participants with a CD4 level between 200 and 499 cells/µL.

All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28.

Eksperimentell: CD4 >= 500

Participants in this arm are stratified in the group with participants with a CD4 level of 500cells/µL or more.

All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Seroconversion rates for monkeypox virus (MPXV) neutralizing antibodies
Tidsramme: 2 weeks after the last vaccine dose

Seroconversion two weeks after administration of two standard doses of MVA-BN, defined as either the appearance of an MPXV neutralizing antibody titre (NT50) greater than or equal to the detection limit for initially seronegative participants or more than doubling of the antibody titre compared to baseline for participants seropositive at baseline

2 weeks after the last vaccine dose

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and reactogenicity of the MVA-BN vaccine in PLHIV
Tidsramme: Up to day 14 and until end of participation

Solicited local AEs (pain, redness, swelling, induration, and itch at the injection site) and systemic AEs (generalized myalgia, headache, fatigue, nausea and/or vomiting, chills and/or fever (≥ 38.0°C)) up to day 14 post vaccination

Unsolicited AEs up to day 14 post vaccination

SAEs until the end of participation

Up to day 14 and until end of participation
Seroconversion rates for vaccinia virus (VACV) neutralizing antibodies
Tidsramme: 2 weeks after last vaccine dose

Seroconversion two weeks after administration of two standard doses of MVA-BN, defined as either the appearance of an VACV neutralizing antibody titre (NT50) greater than or equal to the detection limit for initially seronegative participants or more than doubling of the antibody titre compared to baseline for participants seropositive at baseline.

2 weeks after last vaccine dose
Waning of MPXV neutralizing antibodies in PLHIV
Tidsramme: On day 14 and month 6

The ratio between neutralizing antibody titre against MPXV at 6 months (D28 + 6M) versus 14 days (D28 + 14 days) after administration of two standard doses of MVA-BN.

On day 14 and month 6
Waning of VACV neutralizing antibodies in PLHIV
Tidsramme: On day 14 and month 6

The ratio between neutralizing antibody titre against VACV at 6 months (D28 + 6M) versus 14 days (D28 + 14 days) after administration of two standard doses of MVA-BN.

On day 14 and month 6
Seroconversion rates and IgG antibody titre dynamics against MPXV and VACV antigens in serum
Tidsramme: day 0 (prior to first dose), Day14, Day 28, Day 28+14 days, Day 28+6Months

The absolute IgG antibody titre against the following antigens: A35R, H3L, B2R, A5L, A27L, B6R, E8L and A29L from mpox, and A33R and B5 from vaccinia virus at D14, D28 (second dose), D28+14d, D28+6M after administration of two standard doses of MVA-BN, be defined as either the appearance of Median Fluorescent Values (MFI) greater than the detection limit for initially seronegative participants or more than doubling of the antibody titre compared to baseline for participants seropositive at baseline.

day 0 (prior to first dose), Day14, Day 28, Day 28+14 days, Day 28+6Months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Laurens Liesenborghs, MD, Institute of Tropical Medicine

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. august 2025

Primær fullføring (Faktiske)

11. november 2026

Studiet fullført (Antatt)

31. desember 2026

Datoer for studieregistrering

Først innsendt

17. februar 2025

Først innsendt som oppfylte QC-kriteriene

17. februar 2025

Først lagt ut (Faktiske)

21. februar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere